Cristina Wilbur - Roche Holding Executive
| RHHBY Stock | USD 43.70 0.28 0.64% |
Executive
Ms. Cristina A. Wilbur was Member of the Corporationrationrate Executive Committee, Head Group Human Resources of Roche Holding Ltd since March 2016. She holds BS degree in Accounting from California Polytechnic University. She served at EGG as Human Resources and Payroll Manager and later as Human Resources Director. In 2001 she joined PerkinElmer Optoelectronics as Human Resources Director. In 2002 she joined Roche Diagnostics Corporation as Human Resources Director, where in 2006 she was appointed VicePresident, North America Region Human Resources and Communications. In 2010 she became Senior VicePresident and Global Head of Human Resources at Roche Diagnostics Division. She was Chair of the Board of Directors at International School Basel Reinach AG. since 2016.
| Age | 56 |
| Tenure | 9 years |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sloan Simpson | Novartis AG ADR | N/A | |
| Gideon Blumenthal | Merck Company | N/A | |
| Robert Weltevreden | Novartis AG ADR | 52 | |
| Giovanni MD | Bristol Myers Squibb | 59 | |
| Shannon Klinger | Novartis AG ADR | 49 | |
| Jacquie CFA | Gilead Sciences | N/A | |
| Charles Sawyers | Novartis AG ADR | 62 | |
| Karin Shanahan | Bristol Myers Squibb | 60 | |
| Etienne Jousseaume | Novartis AG ADR | N/A | |
| Kimberly Jablonski | Bristol Myers Squibb | N/A | |
| Linda Higgins | Gilead Sciences | 63 | |
| Steffen Lang | Novartis AG ADR | 58 | |
| Vasant MD | Novartis AG ADR | 49 | |
| Vasant Narasimhan | Novartis AG ADR | 48 | |
| Jennifer JD | Merck Company | 46 | |
| Jeffrey Pott | AstraZeneca PLC ADR | N/A | |
| Peter Dannenbaum | Merck Company | N/A | |
| Pierre Chancel | Sanofi ADR | 68 | |
| John Tsai | Novartis AG ADR | 54 | |
| Deborah JD | Gilead Sciences | 60 | |
| Bilal Piperdi | Gilead Sciences | N/A | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Claudia Bockstiegel, G Counsel | ||
| Bruno Eschli, Head Relations | ||
| Johannes MD, Head Devel | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Alan Hippe, Chief Financial and IT Officer | ||
| Severin Schwan, CEO and Executive Director | ||
| Pascale Schmidt, Chief Officer |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 293.22 B | |||
| Shares Outstanding | 6.4 B | |||
| Shares Owned By Institutions | 1.27 % | |||
| Price To Earning | 17.56 X | |||
| Price To Book | 9.81 X | |||
| Price To Sales | 3.99 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Roche OTC Stock Analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.